Latest Erectile Dysfunction News

LTR Pharma reports a 93% response rate in men seeking convenience and spontaneity with SPONTAN, alongside a 64% response in post-prostatectomy patients, highlighting potential for its rapid-onset intranasal ED treatment in challenging populations.

EVE Health Group has progressed its Libbo pilot clinical study for erectile dysfunction with dosing set for Q4 2026 and achieved a major solubility breakthrough for apixaban, while appointing Ben Rohr as CEO to drive commercial growth.

LTR Pharma’s SPONTAN shows rapid absorption in Phase II interim data while securing key US commercial deals for ROXUS, setting the stage for a US market entry later this year.

LTR Pharma has locked in a comprehensive commercial agreement with Strive Pharmacy, cementing its manufacturing and fulfilment infrastructure for the upcoming US launch of ROXUS®.

LTR Pharma has formalised its US commercialisation strategy by signing a definitive agreement with telehealth leader Shed, targeting at least 150,000 ROXUS units in the first year through digital men’s health platforms.

LTR Pharma’s intranasal spray OROFLOW® has secured ethics approval for a clinical study targeting oesophageal motility disorders, marking its first foray beyond erectile dysfunction. The study, led by Dr Peter Wu, aims to validate a non-invasive alternative for swallowing difficulties in a market projected to reach US$8.1 billion by 2034.

LTR Pharma has confirmed it disclosed a binding US commercialisation agreement for ROXUS promptly after signing, responding to ASX scrutiny over pre-announcement trading activity.

LTR Pharma has locked in Strive Specialties as its exclusive US pharmacy fulfilment partner for ROXUS, marking a critical step towards commercial launch in the US erectile dysfunction market.

LTR Pharma has secured a binding US telehealth commercialisation framework for its intranasal erectile dysfunction treatment ROXUS, committing to at least 150,000 prescriptions in the first year and granting exclusivity to Shed Holdings' platform.

LTR Pharma highlights SPONTAN's 5x faster absorption and validated safety, backed by over 1,000 Australian prescriptions and strategic partnerships as it targets FDA approval and US market entry.

EVE Health Group has begun commercial sales of Libbo, an oral dissolving film for erectile dysfunction, supported by a new digital men’s health platform. The company also expanded its pharmaceutical pipeline and secured $1.3 million in fresh capital to fund ongoing development and commercialization.

LTR Pharma has wrapped up recruitment for its SPONTAN Phase II pharmacokinetic study, with interim results expected soon to bolster FDA approval efforts. Meanwhile, US commercial talks for ROXUS advance cautiously under the FDA 503(a) personalised medicine pathway.